Cosmo Highlights Strategic AI and GI Innovation Agenda at Digestive Disease Week(R) 2025

Rhea-AI Summary

Cosmo (CMOPF) is participating in Digestive Disease Week® (DDW) 2025 in San Diego, California from May 3-6. The company's leadership team is conducting strategic meetings with key opinion leaders, innovators, and potential partners in AI and gastrointestinal (GI) drug development. DDW, attracting over 13,000 gastroenterologists, researchers, and industry leaders annually, serves as a platform for Cosmo to advance its position in AI-powered endoscopy and GI therapeutics.

CEO Giovanni Di Napoli emphasized DDW's importance as the epicenter of GI innovation. The company has also convened its AI Advisory Board at the event to guide strategic priorities and accelerate development across its AI platform. Cosmo's participation demonstrates its commitment to advancing GI care through technology integration and strategic partnerships.

Dublin, Ireland--(Newsfile Corp. - May 5, 2025) - Cosmo is attending this year’s Digestive Disease Week® (DDW), held in San Diego, California from May 3-6, where its leadership team is advancing a focused agenda of strategic meetings with key opinion leaders (KOLs), innovators, and potential partners in AI and gastrointestinal (GI) drug development.

DDW is the world’s premier gathering in the field, attracting each year over 13,000 gastroenterologists, researchers, and industry leaders from around the globe. Cosmo is leveraging this unique setting to deepen relationships and explore new collaborations that align with its strategy to lead in AI-powered endoscopy and GI therapeutics.

“DDW is the epicentre of innovation in GI, and we are here to make meaningful progress,” said Giovanni Di Napoli, CEO of Cosmo. “We’re engaging with some of the brightest minds and most visionary partners to drive our AI and drug development efforts forward. The future of GI is being shaped now, and Cosmo is committed to being a catalyst in that transformation.”

In parallel, Cosmo has convened its AI Advisory Board at DDW, bringing together world-class experts to guide the company’s strategic priorities and fast-track development across its AI platform.

Cosmo’s presence at the Digestive Disease Week® underscores its long-term commitment to advancing GI care through a unique integration of technology, science, and execution. The Company continues to invest in partnerships that will unlock new value for physicians and patients across the globe.

About Cosmo
Cosmo Pharmaceuticals N.V. is committed to revolutionizing healthcare and transforming people’s lives by researching and developing innovative products that tackle unfulfilled healthcare demands. As a pharmaceutical company, Cosmo is active in the areas of Healthtech/AI, dermatology, gastroenterology and contract manufacturing & development. For the commercialization and distribution of its products, Cosmo collaborates with leading partners worldwide, including Medtronic and Sun Pharma. Founded in 1997, Cosmo is headquartered in Dublin (Ireland) and has offices also in San Diego (USA), and Lainate/Rome/Catania (Italy). The Company has approximately 330 employees at the end of 2024, all dedicated to making a significant impact in the field of healthcare. For more information, please visit www.cosmopharma.com.

Financial calendar

Ordinary Annual General Meeting of Shareholders	May 30, 2025
Jefferies Healthcare Conference, New York	June 3-5, 2025
Investor Day, Zurich	July 1, 2025
2025 Half-Year Results and Report	July 23, 2025

 

For further information, please contact:
Cosmo Pharmaceuticals Investor Relations, investor.relations@cosmopharma.com

Disclaimer
Some of the statements in this press release may be forward-looking statements or statements of future expectations based on currently available information. Such statements are naturally subject to risks and uncertainties. Factors such as the development of general economic conditions, future market conditions, unusual catastrophic loss events, changes in the capital markets and other circumstances may cause the actual events or results to be materially different from those anticipated by such statements. Cosmo does not make any representation or warranty, express or implied, as to the accuracy, completeness or updated status of such statements. Therefore, in no case whatsoever will Cosmo and its affiliate companies be liable to anyone for any decision made or action taken in conjunction with the information and/or statements in this press release or for any related damages.

Attachments

250505_Cosmo Pharma_Media Release_DDW 2025_EN_final

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/250781

FAQ

What is Cosmo's (CMOPF) main focus at Digestive Disease Week 2025?

Cosmo is focusing on strategic meetings with key opinion leaders, innovators, and potential partners in AI and gastrointestinal (GI) drug development, while also convening its AI Advisory Board to guide strategic priorities.

When and where is Digestive Disease Week 2025 being held?

Digestive Disease Week 2025 is being held in San Diego, California from May 3-6, 2025.

Who is the CEO of Cosmo (CMOPF) and what did he say about DDW 2025?

Giovanni Di Napoli is Cosmo's CEO, and he stated that 'DDW is the epicentre of innovation in GI, and we are here to make meaningful progress.'

What are Cosmo's (CMOPF) strategic priorities in gastrointestinal care?

Cosmo is focused on leading in AI-powered endoscopy and GI therapeutics, investing in partnerships to unlock new value for physicians and patients globally.